{"id":"W2137268781","doi":"10.1158/1535-7163.mct-09-0960","title":"Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada); Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canada Research Chairs; GlaxoSmithKline","keywords":"Topotecan; Medicine; Pazopanib; Ovarian cancer; Pharmacology; Paclitaxel; Irinotecan; Chemotherapy; Cyclophosphamide; Ovarian carcinoma; Cancer; Oncology; Internal medicine; Sunitinib; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003226136,0.0006461433,0.000739091,0.0004428555,0.0002317613,0.0004992913,0.0003956201,0.000424083,0.001304285],"category_scores_gemma":[0.0002278377,0.000237566,0.0003043758,0.0003672368,0.000316017,0.0003588409,0.0001925428,0.001395732,0.0001962856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005264979,"about_ca_system_score_gemma":0.0009400384,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001600493,"about_ca_topic_score_gemma":0.004412394,"domain_scores_codex":[0.9997736,0.00005532996,0.00001507819,0.00002934032,0.00005555504,0.00007105387],"domain_scores_gemma":[0.9998584,0.00002291986,0.00002531166,0.0000152666,0.00001459349,0.0000635714],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004771585,0.006036404,0.000700695,0.0001508215,0.00006132445,0.0001119941,0.00006282927,0.001548935,0.9712804,0.0002782439,0.0005389132,0.01445775],"study_design_scores_gemma":[0.002325476,0.07252346,0.007325383,0.00001733842,0.0001714101,0.0004152673,0.00004813679,0.002867227,0.9108428,0.0001057117,0.003334254,0.0000234136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959211,0.00110151,0.0008575033,0.0001516076,0.00004881649,0.000246089,0.0004654447,0.0000740883,0.001133764],"genre_scores_gemma":[0.9954073,0.0009235989,0.001395992,0.000055091,0.00002178024,0.0002002153,0.0007779779,0.00001763185,0.001200308],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001600493,"threshold_uncertainty_score":0.004363298,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03021178287455396,"score_gpt":0.3444115221306979,"score_spread":0.314199739256144,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}